Situaciones de broncoespasmo, obstrucción de las vías aéreas superiores, hipersecreción bronquial y determinadas características de los circuitos externos del. Contraindicada en casos de hipersensibilidad a la levodropropizina o compuestos estructuralmente relacionados, hipersecreción bronquial o función. Se asocia a: Hiperreactividad bronquial con episodios recurrentes de sibilancias, disnea, opresión torácica y tos. Obstrucción bronquial difusa.

Author: Sarr Visida
Country: Canada
Language: English (Spanish)
Genre: Photos
Published (Last): 17 April 2013
Pages: 25
PDF File Size: 17.72 Mb
ePub File Size: 18.24 Mb
ISBN: 740-6-60523-864-3
Downloads: 72705
Price: Free* [*Free Regsitration Required]
Uploader: Tygoshakar

However, remote access to EBSCO’s databases from non-subscribing institutions is not allowed if the purpose of the use is for commercial gain through cost reduction or avoidance for a non-subscribing institution.

Pisi G, Chetta A. Eur J Respir Dis Suppl. Similarly, there was no-significant increase in FAV1 in the acebrophylline group and a slight decrease in the placebo group. Hematology, blood chemical values bronqujal urinalysis.

Prueba broncodilatadora | Trisán Alonso | Revista de asma

Infection Control Group Pseudomonas aeruginosa infection in people with cystic fibrosis. Brain B, et al.

Inhaled mannitol for non-cystic fibrosis bronchiectasis: Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: An elevated bronchodilator response predicts large airway inflammation in mild asthma.

Effects of long-term azithromycin therapy on airway oxidative stress markers in non-cystic fibrosis bronchiectasis. The response of patients with purulent bronchiectasis to antibiotics for four months. Eur Respir J Suppl. At the end of treatment a reduced progression and severity of oxidative stress in the acebrofilin group was observed. Randomized code was open and the final sample distribution was: This abstract may be abridged.


Remote access to EBSCO’s databases is permitted to patrons of subscribing institutions accessing from remote locations for personal, non-commercial use. J Allergy Clin Immunol. Servicio de ayuda de la revista. Chhabra SK, Bhatnagar S. Airway responsiveness to a bronchodilator aerosol.

Monografías de Archivos de Bronconeumología

Repeatibility of spirometry in 18, adult patients. TS, Chalmers JD, et al. Clinical predictors and outcomes of consistent bronchodilator response in the childhood asthma management program.

No warranty is given about the accuracy of the copy. Curr Opin Pulm Med.

No adverse events were reported with acebrophylline. Phase 3 efficacy and safety data from randomized, multicentre study of liposomal amikacin for inhalation Arikace compared with Tobi R in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa.

Effects of longterm use of macrolides in patients with non-cystic fibrosis bronchiectasis: Scheinberg P, Shore E.

Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis. Acute additive effect of montelukast and beclomethasone on AMP induced bronchoconstriction. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Association between fraction of exhaled nitrous oxide, bronchodilator response and inhaled corticosteroid type. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis.


Inhaled antibiotics for stable non-cystic fibrosis bronchiectasis: Clinical interpretation of airway response to a bronchodilator: Outcomes of Pseudomonas eradication therapy in patients with non—cystic fibrosis bronchiectasis. A genome-wide association study of bronchodilator response in asthmatics. However, users may print, download, or email articles for individual use. Response to isoproterenol in a general population sample.

A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: Inhaled steroids in patients with bronchiectasis.

Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas. Measurement of reversibility of airways obstruction: Cochrane Database Syst Rev.

The disease-modifying effects of twiceweekly oral azithromycin in patients with bronchiectasis.